Gilde Healthcare exits Stat-DX

Gilde Healthcare led a €31m funding round for Stat-DX in 2016, which enabled the company to accelerate its growth, build in-house manufacturing capabilities, expand its product pipeline, obtain European market approval and prepare to launch on the market.

Qiagen is a Dutch provider of technologies for molecular diagnostics, applied testing and academic and pharmaceutical research. The company operates in 25 countries, and is listed on the New York and Frankfurt stock exchanges. In 2017, Qiagen generated adjusted operating income of $371.5m from revenues of $1.42bn.

Company
Founded in 2010 and based in Barcelona, Stat-DX focuses on the development, manufacture and commercialisation of diagnostic tools for infectious diseases and critical care. The company has developed a platform called QIAstat-DX that will aid diagnosis of respiratory and gastrointestinal infections, and cancer.

According to the company, the platform is able to provide qualitative and quantitative insights into the precise cause of various infections in around one hour. The company will launch its first two tests in Europe in mid-2018.

People
Stat-DX – Gerard Vaillant (chairman).
Gilde Healthcare – Arthur Franken (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• Southern Europe
• Healthcare
• Spain
• Trade sale
• Gilde Investment Management